Brief Papers

Serum soluble interleukin-2 receptor predicts early remission in patients with recent-onset rheumatoid arthritis treated with a single disease-modifying antirheumatic drug

A. Kuuliala, M. Leirisalo-Repo, T. Möttönen, P. Hannonen, M. Nissilä, H. Kautiainen, M. Korpela, H. Julkunen, M. Hakola and H. Repo, for the FIN-RACo Trial Group